The
drugmaker said it was ready to pursue mRNA on its own following
its experience in the past year working on the COVID-19 vaccine,
the WSJ reported, citing an interview with Pfizer Chief
Executive Officer Albert Bourla.
It did not, however, disclose any details about the viruses it
was targeting.
Pfizer and BioNTech did not immediately respond to Reuters
requests for comment.
Pfizer/BioNTech and Moderna's COVID-19 vaccines, authorized for
emergency use in the United States, use mRNA technology.
The success of the technology is prompting drug developers to
consider its use in other areas of medicine beyond vaccines,
attracting billions of dollars in investment.
(Reporting by Manojna Maddipatla in Bengaluru; Editing by Anil
D'Silva)
[© 2021 Thomson Reuters. All rights
reserved.] Copyright 2021 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content.
|
|